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Abstract
The objective of this work is to elucidate various essential drugs in the Brazil, Russia, India, China and South 
Africa (BRICS) countries. It discusses the opportunities and challenges of the existing biotech infrastructure 
and the production of drugs and vaccines in member states of the BRICS. This research is based on a systematic 
literature review between the years 2000 and 2014 of documents retrieved from the databases Embase, PubMed/
Medline, Global Health, and Google Scholar, and the websites of relevant international organizations, research 
institutions and philanthropic organizations. Findings vary from one member state to another. These include useful 
comparison between the BRICS countries in terms of pharmaceuticals expenditure versus total health expenditure, 
local manufacturing of drugs/vaccines using technology and know-how transferred from developed countries, and 
biotech entrepreneurial collaborations under the umbrella of the BRICS region. This study concludes by providing 
recommendations to support more of inter collaborations among the BRICS countries as well as between BRICS and 
many developing countries to shrink drug production costs. In addition, this collaboration would also culminate 
in reaching out to poor countries that are not able to provide their communities and patients with cost-effective 
essential medicines. 
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Introduction 
Since 2010, five newly emerging economies collectively known 
as ‘BRICS’ (Brazil, India, Russia, China and South Africa) have 
caught the imagination, and scholarly attention, of political 
scientists, economists and development specialists. The 
prospect of a unified geopolitical bloc, consciously seeking to 
reframe international (and global) health development with 
a new set of ideas and values, has also, if belatedly, begun to 
attract the attention of the global health community (1–4). But 
what influence, if any, do the BRICS wield in global health, 
and, if they do wield influence, how has that influence been 
conceptualized and recorded in the literature? 
The total population of the BRICS is estimated in 2013 at 
3 billion people with a combined nominal GDP of 14.8 
trillion US dollars (5). These fast-growing economies and 
all G20 members exert considerable influence on regional 
and global affairs. However, the BRICS are currently 
encountering important domestic health challenges. These 
countries announced in many meetings their commitments 
to increasingly engage in global health. During the 2011 
Ministers of Health meeting, the BRICS clearly indicated the 
potential benefits of collaboration and ultimately decided to 
tackle together common health challenges (6).
In a recent study, the BRICS bloc claims to constitute 
a paradigm shift in global health development from 
international relations framework which differentiates 
between material capabilities, institutions and ideas in order 
to compare different historical structures or ‘frameworks 
for action’ (7). This study infers some sort of skepticism 
in the context of global health a sense that collectively, the 
BRICS countries focus more rhetoric rather than practice. 
However, these countries have implemented a progressive 
approach to global health when considering support for 
Research and Development (R&D) into new drugs, products 
and technologies; and response to Non-Communicable 
Diseases (NCDs). 
An empirical analysis illustrates how and why the BRICS 
summit system has governed global health. Essentially, 
the BRICS bloc is fully committed to its health-related 
commitments by creating the BRICS health ministers’ 
institution and engaging with other multilateral institutions. In 
addition, and due to the lack of any significant leadership from 
the G8 and G20, the BRICS countries are leading the world 
among global plurilateral summit institutions in governing 
NCDs (8).
For over 35 years, the World health Organization (WHO) has 
launched the concept of essential medicines. Updated versions 
are released every two years since 1977. The current versions 
are the 18th WHO Essential Medicines List for Adults and 
the 4th WHO Essential Medicines List for Children updated 
in April 2013. As of 2011, the WHO Model List included 
350 Essential Medicines [Essential Drug List (EDR)] and the 
National EDL of India list included 348 (9). In China, the 
2004 list includes 1260 Chinese herbal preparations and 773 
chemical and biological medicines products (10).
While many developing countries have been engaged in 
manufacturing relatively cost-effective drugs, the cooperation 
between BRICS and developing countries is leading towards 
distribution of lower-cost drugs compared to developed 
markets (11). For example, Brazil and Cuba are collaborating 
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to produce meningitis A vaccine for Africa (12).  In addition, 
Bio-Manguinhos (Brazil) and the Finlay Institute (Cuba) were 
found to be the most suitable suppliers of a meningitis vaccine 
by the WHO when both institutions collaborated during the 
outbreak of meningitis in 2007 and neither company alone 
could have conducted the job effectively. Moreover, Brazil is 
involved in building pharmaceutical plants in Africa and more 
specifically in Mozambique and Namibia to manufacture 
generic anti-retroviral medicines. Brazil also pledged 80 
million US dollars to rebuild the health system in Haiti after 
the 2010 catastrophic earthquake (13). This paper explores 
the collaborations among the BRICS countries as well as 
between the BRICS and developing countries to shrink drug 
production costs. 
The Indian firm Biological E is collaborating with the 
International Centre for Diarrhoeal Disease Research 
(ICDDR; Bangladesh) and co-developed a vaccine candidate 
to prevent cholera as this disease is very common in 
Bangladesh and eastern India. The two firms agreed that once 
this candidate proves to be effective and safe, Biological E 
would go ahead in manufacturing the vaccine (13).
China and Egypt also teamed in an entrepreneurial 
collaboration where production of recombinant insulin takes 
place in Egypt using technology from China. Hence, a local 
source of insulin was made available in Egypt and conveniently 
cheaper than the imported product (14).
In July 2014, the BRICS countries met and discussed their 
commitment to create a joint funding where health is a 
priority area to be supported and ensure that innovation is 
both accessible and affordable to those in need. Innovation 
in healthcare is witnessing many shortcomings including 
for example Tuberculosis (TB) which suffers from chronic 
under-investment due to a less attractive commercial market 
mainly in poor countries. A greater support for innovative 
mechanisms are needed to minimize the gaps in health and 
medical research especially the ones that promote collaboration 
and ensure sustainable funding to tackle diseases in poor and 
developing countries (15).  
The entire world health community is watching very 
closely the innovative public health programs and policies 
undertaken by the BRICS countries. Their main contributions 
to global health include genetic drugs to manage HIV and 
TB as well as providing diverse health service delivery and 
innovative diagnostic tools (16). 
This study helps to identify opportunities in drug production 
in inter-collaborations among BRICS, as wells as BRICS and 
developing countries. It also illustrates various approaches and 
strategies that drive such collaborations forward and eventually 
culminate in improving global health and local economies. 
Methods
Literature reviews are known for their important summaries 
to the scientific field for addressing research issues by using 
explicit methods to find, select, assess and then analyze the 
related research studies included for the review.
Search strategy and selection criteria
This research is based on a literature review between the years 2000 
and 2014 of documents retrieved from the databases Embase, 
PubMed/Medline, Global Health, and Google Scholar, and 
the websites of relevant international organizations, research 
institutions and philanthropic organizations. The following 
Mesh terms were used: “healthcare in BRICS”, “healthcare 
challenges in BRICS”, “essential medicine in BRICS”, “essential 
drugs production in BRICS”, “vaccines in BRICS”, “health 
biotech in BRICS”, “pharmaceutical collaboration in BRICS”, 
“drugs manufacturing in BRICS”, “health and pharmaceutical 
policies in BRICS”, and “global health in BRICS”. 
Data extraction 
After completing the search, the selected documents were 
summarized and categorized based on the topic and its 
implications. The results were synthesized using a framework 
of influence developed for the review from the health, 
economics and political science literature.
Data collection and analysis
In this review, the collected cases of collaboration in drug 
production discussed how to improve global health and local 
economies within the BRICS countries. During the collection 
process, numerous sources were used to conduct the search for 
such literature including search engines, specialized databases, 
and official websites of multinational firms involved in drug 
production in the BRICS region. The findings generated from 
all included studies formed the themes to critically analyze 
drug production in the BRICS bloc needed to improve global 
health and local BRICS economies. This study does not 
provide a detailed data quality.
Results
The initial search of databases and websites yielded 947 
documents. Exclusion criteria narrowed the number of 
documents to 79 journal articles and 17 reports. A few 
studies provided sustained analysis of the BRICS’ collective 
influence (17); the overwhelming tendency was to describe 
individual BRICS countries influence. Although influence 
was predominantly framed by the BRICS countries’ material 
capability, there were examples of institutional and ideational 
influence – particularly from Brazil. Individual BRICS 
countries were primarily ‘opportunity seekers’ and region 
mobilisers but with potential to become ‘issue leaders’ and 
region organizers.
 
Production of drugs and vaccines in Brazil, Russia, India, China 
and South Africa (BRICS)
Currently, the BRICS countries possess the required 
infrastructure and the capacity to produce generics of many 
drugs for both their domestic markets and many Low- and 
Medium-Income Countries (LMICs). In addition, these 
countries are also capable to supply Active Pharmaceutical 
Ingredients (APIs) that are needed for manufacturing generics 
and on-patent drugs in LMICs (18). Similarly, other reports 
also state that the manufacturing of these ingredients is mainly 
occurring in the industrialized and developed world with an 
exception of a few emerging BRICS members such as Brazil, 
China, and India (19).     
The influence of the BRICS alliance on the issue of “access 
to medicine” is significant during the prospective showdown 
between the BRICS alliance and the developed countries 
(20,21). For example, the patent-based pharmaceutical 
manufacturers might as well still concentrate solely on the 
developed countries and will continue to be protected by 
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vigorous intellectual property laws (22). Figure 1 illustrates how 
pharmaceuticals expenditure versus total health expenditure 
in the BRICS region during the period 1995–2010 where India 
leads pharmaceuticals expenditure compared to other BRICS. 
While Figure 2 depicts the total pharmaceutical expenditure 
per capita USD in BRICS and here Brazil leads other BRICS. 
In Brazil, there has been a strategy to prioritize domestic 
production of essential medicines which represents a 
determinant factor to increase and sustain access. The majority 
of vaccines are manufactured locally and immunization 
rates reached very high levels and particularly with measles 
coverage reaching 99% (23).
The goal of the Russian strategy Pharmaceutical 2020 is to 
ensure that local drugs production would cover 50% of all 
generic drugs by 2017 and 50% of all innovative drugs by 
2020. The implementation of  this strategy was initiated by the 
Russian government as it secured  4 billion dollars in March 
2011 and provided the local drug producers with preferential 
access to state reimbursement lists which encourage foreign 
companies to invest in Russia and become “localized” (24). 
This led to many cases of acquisitions and mergers which 
took place in Russia. For example, Sanofi-Aventis acquired 
controlling stake in the Russian manufacturer of insulin 
ZAO Bioton Vostok, hence became a local pharmaceutical 
producer; and Merck Sharp & Dohme merged with Schering-
Plough in Russia. In addition, more than 140 contracts have 
Figure 1. Pharmaceuticals expenditure versus total health expenditure 
in BRICS (Source NHA 1995–2010)
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Figure 2. Total pharmaceutical expenditure per capita USD in BRICS 
(Source NHA 1995–2010)
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been approved such as the development of technologies for 
the manufacture of EDL, transfer of technology and know-
how for innovative drugs and pre-clinical and clinical drug 
research (25). 
In order to promote local production of active pharmaceutical 
ingredients in South Africa, the Italian government accepted to 
fund a 9 million euros United Nations Industrial Development 
Organization (UNIDO)-coordinated project. This project 
helps to build up capacity for Good Manufacturing Practice 
(GMP)-compliant line of production to manufacture vaccines 
in the country (26). 
Since many drugs are due to lose their patent protection in South 
Africa, the demand for essential medicines including generic 
antibiotics and over-the-counter drugs are expected to be on 
the rise.  The number of local pharmaceutical firms is limited 
and most of them are focusing on production of chemicals and 
generic APIs and the last step synthesis is completed by the 
local subsidiaries of international pharmaceutical firms which 
are still dominating the industry (27,28). The multinational 
pharmaceutical companies were reported to source one pint 
5% of active ingredients, 36% of packing materials and 20% of 
excipients locally. The rest of inputs are usually imported from 
India and China, resulting in a relatively low value added in 
the entire pharmaceutical value chain (29).
Infrastructure of India’s biotech and drugs production sectors 
and the private drug and vaccine manufacturers in India 
played major roles even in developing countries through 
increasing access to generic drugs. 
Even though India showcased its low-cost production, 
however, the country has also clearly revolutionized health 
service delivery by crafting new approaches which have been 
adopted in various countries. This includes TB research center 
in Chennai that helped to develop the Directly Observed 
Treatment, Short-Course (DOTS). About 40 biomedical 
research centers such as the well-known Department of 
Biotechnology (DBT) are all funded through the government. 
The DBT has been pushing for innovating healthcare services 
in India including new vaccines for rotavirus. 
The biotech companies not only kept investing in very lucrative 
R&D programs but also they also took advantage of the 
abundance of highly educated scientists, medical practitioners 
and IT professionals in India. 
As of March 2012, India made a commitment to increase 
scientific collaboration with developing countries in a number 
of areas such as capacity building and knowledge transfer 
and adoption (30). For example, the Mumbai-based drug 
manufacturer Lupin Ltd. has established a partnership with 
Farmanguinhos and the Brazilian Ministry of Health (MoH) 
to support the introduction of a four-in-one combination 
TB drug. This partnership states that Lupin will transfer the 
technology and the know-how to help Farmanguinhos launch 
it local manufacturing facility in Brazil (31). 
Exports of India’s pharmaceutical increased during the years 
2006–7 in the USA and Europe and reached 57.8%. However, 
those exports represent only 14.1% in Africa during the same 
period. For example, the sales from pharmaceutical products 
of the Indian pharmaceutical company Ipca Labs in Africa 
represent only 7.7%, where Europe and the USA combined 
represent about 14.1% of the firm’s total income (32).
In India, 72 WHO pre-qualified vaccines are produced by 8 
local manufactures and between 60% and 80% of all vaccines 
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procured by UN agencies are also manufactured locally. This 
has led to position India as the largest provider of a high-
quality and affordable vaccines for the developing world (33).
These examples of collaboration between Indian firms and 
others from the BRICS and/or developing countries will 
reinforce and sustain the ability to manufacture and produce 
drugs cost-effectively and consequently improve global health. 
Drugs production in China by local and multinational firms
The Swiss multinational pharmaceutical company Novatis 
completed acquisition of majority stakes in Zhejiang Tianyuan 
Bio-Pharmaceuticals. This will ultimately lead to increasing 
local production of vaccines in China (34). On the other hand, 
Chinese pharmaceutical companies are facing tough times 
in accessing American and European markets. The main 
factor related to this issue is due to the higher standards and 
requirements needed in obtaining official drug certifications 
from Western Food and Drug Administrations (FDAs).  
As of August 2010, there were about 1,200 APIs manufacturers 
in China who are able to produce more than 1,500 categories 
of API.  The country was ranked No.1 in the world in terms of 
production output of ingredients for penicillin, vitamins and 
antipyretics and analgesics (35). 
The Chinese Pharmaceutical Shenzhen Hepalink is among 
the world the top largest producers of heparin sodium active 
pharmaceutical ingredients and produces mainly injectable 
grade heparin products (36). It is also one of the very few 
Chinese pharmaceutical firms to be both American FDA and 
European Union CEP certified. 
Jiangsu Hengrui Medicine is the largest Chinese manufacturing 
base of antineoplastics and surgical medicine. It also provides 
drugs for a range of treatments including cardiovascular 
disease, endocrine ailments, antibiotics and for infusions 
during surgery. The firm manufactures and distributes 
pharmaceutical tablets, injections in the local market. Recently, 
it passed the inspections of the FDA and the European Union 
and hence was allowed to sell injection products in both the 
American and the European markets (37).
In 2005, drugs producers in Shandong manufactures averaged 
20 essential medicine product licenses and around 60% of 
licensed products actually produced. In Gansu province, 
drugs producers averaged 41 licenses, however, only half 
of the products were actually produced. Therefore, the 
production output of essential medicines was not correlated 
with manufacturer sales volumes. In Shandong province, 8 
out of 10 most frequently produced products were Western 
medicines. Meanwhile in Gansu, glucose injection was one 
of the most frequently manufactured products but the only 
Western medicine (10).
The German-based chemical and pharmaceutical company 
Bayer started producing drugs in China since 1997 and 
particularly focusing on Glucobay which represents China’s 
best-selling diabetes medicine (38).
In 2011, the Chinese pharmaceutical Nanjing MeiRui Pharma 
Co, which is well-known for producing urology and allergy 
products, has been acquired by the British multinational 
pharmaceutical GlaxoSmithKline (GSK) (35). Besides the 
summer of 2013 scandal that connected Glaxo executives 
in bribery ordeal in China, GSK has been very active in 
signing strategic alliances with many Chinese pharmaceutical 
companies (35). 
The European pharmaceutical company Nycomed (acquired 
by the Japanese pharmaceutical giant Takeda in 2011) became 
controlling shareholder of Guangdong Techpool Biopharma 
in 2010. Techpool focuses on manufacturing and marketing 
of biologic drugs derived from natural sources and various 
innovative protein drugs such as Iron Sucrose which is used 
for the treatment of iron deficiency anemia and patients who 
have chronic kidney disease (39).
This type of acquisition and mergers would even lead to not 
only decrease the overall drug production costs but also to 
expedite the drug innovation process in the future. 
Collaboration of Indian and Chinese biotech industries
Given that China and India together account for about half of 
the poor people in the world, it is important to strike a balance 
or at least observe very closely the relationship between local 
producers and domestic drug consumers. There are many 
profitable biotech and pharmaceutical companies in China 
and India who are collaborating in providing health services 
to the poor. Cipla, Ranbaxy, and Hetero represent good 
examples where these companies are able to manufacture 
low-cost antimalarial and antiretroviral therapies in Africa. 
Shanghai United Cell Biotech successfully designed and 
produced the only tablet formulation of cholera vaccine with 
the collaboration with its Indian partner Pune, along with its 
138-country global distribution network and relationships 
with United Nations Children’s Fund (UNICEF), supplies 
one of every two doses of vaccine given in the entire world. 
Shantha Biotechnics located in Hyderabad reported to have 
been able to develop a cost-effective manufacturing process 
for hepatitis B vaccine (Shanvac-B) (40).   
This huge potential of the Indian and Chinese biotech 
industries will help in shrinking the production costs of many 
drugs. In addition, collaboration between Indian and Chinese 
firms and others within the BRICS, developed/developing 
countries would even help poor countries to improve access to 
drugs to many disadvantaged populations. 
Discussion 
The BRICS economies are expected to exceed the G7 nations 
by 2050. On the other hand, non-communicable diseases are 
poised to be Africa’s largest killer. David Gold, attorney and 
principal of Global Health Strategies, argued that the BRICS 
are also expected to become key players in curing cancer by 
funding R&D in cancer and cancer drug development (41). 
This represents an opportunity where collaboration between 
the BRICS countries needs to be fostered within a framework 
of transparent rules, policies, and regulations.  
The BRICS countries have successfully produced and 
enriched the world community with many vaccines. 
Table 1 below illustrates an example of vaccine production in 
the BRICS region (17). 
In order to promote global health, international organizations 
would be more effective in pushing for an effective cooperation 
between BRICS and developing countries by advocating 
companies to pool their efforts when conducting research, 
marketing and developing medicines. Consequently, this 
initiative would help to supply drugs, vaccines and diagnostics 
to the poor and developing countries. This type of collaboration 
is a key driver in fulfilling drugs production shortages and 
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Table 1. Vaccines produced in the BRICS countries
Country Vaccines produced
Brazil Influenza, pneumococcal conjugate, rabies, and rotavirus.
Russia
Brucellosis, diphtheria, tetanus, tularemia, varicella, 
tularemia, mumps, and hepatitis for children and adults.
India
Pandemic influenza, seasonal influenza, typhoid 
conjugate, and rubella.
China
Anthrax, hemorrhagic fever with renal syndrome, 
hepatitis A, influenza H1N1, tick-borne encephalitis, 
and tracheitis.
South Africa Hepatitis B.
BRICS= Brazil, Russia, India, China and South Africa
demands. To strengthen BRICS collaboration even through 
unreliable medicine supply systems (42), countries like China, 
India as well as Russia have the infrastructure and built up the 
capacity for producing cost-effective drugs (43). 
Inter collaborations between the BRICS countries like 
Brazil, China and India need to set the pace and create more 
incentives to increase local production of drugs with LMICS 
countries. This initiative helps to increase access to medicines 
and contribute to economic and industrial development and 
to technological capacity and to achieve the Millennium 
Development Goal (MDG) targets for access to medicines 
(44–49). The know-how reservoir for local drugs production 
would not only serve to improve public health but also 
include pharmaceutical manufacturing and marketing, drug 
regulatory and registration issues, intellectual property, tax 
and tariff policies, and trade and commerce (50). 
The BRICS countries have struggled for decades to be able to 
provide access to medicines as well as to satisfy public health 
requirements. The current reservoir of research and know how 
are adequate for these countries to plan and execute strategies 
to overcome existing and common health challenges. The 
BRICS countries need to joint efforts and explore cooperation 
initiatives and evidently joint funding opportunities that give 
rise to health/medical innovations that are above all accessible 
and reasonably priced for the disadvantaged and poor 
communities.
The main motivation of this work is to shed light on health 
biotechnology challenges in the BRICS region including the 
availability and production of drugs and vaccines and to report 
on the huge existing infrastructure and its impact on global 
health. This work also illustrates how the BRICS countries 
could collaborate on drugs production and be able to lower the 
cost of at least the essential medicines and ultimately improve 
access to drugs particularly in developing and poor countries.
This work illustrates various opportunities of collaborations: 
inter BRICS, and between BRICS and developing countries. 
In addition, the contribution of this work is to showcase 
the status of existing infrastructures of this industry 
and opportunities to excel through collaboration. It also 
reveals various  approaches and strategies that drive such 
collaborations forward and eventually culminate in improving 
global health and local economies.
 
Conclusion
Though small in number, the written output on BRICS 
influence in global health has increased significantly over 
the last few years. Whilst it may still be ‹early days› for 
newly-emerging economies influence in global health to 
have matured, this paper argues that there is scope to further 
develop the concept of influence in global health, but also to 
better understand the ontology of groups of countries such 
as BRICS. The BRICS countries have made a number of 
important commitments towards reforming global health, but 
if they are to be more than a memorable acronym they need to 
start putting those collective commitments into actions. 
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